T cell targeted strategies for improved efficacy and safety of specific immunotherapy for allergic disease

Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry

Volumn 12, Issue 3, 2013, Pages 201-222

  Rolland, Jennifer M ^a   Prickett, Sara ^a   Gardner, Leanne M ^a   O'Hehir, Robyn E ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Adjuvant; Allergen; Antigen presenting cell; DNA vaccine; Immunotherapy; Mutant allergen; Regulatory T cell; T cell epitope peptide

Indexed keywords

ALLERGEN; ALPHA INTERFERON; BETA INTERFERON; DER F 2 PEPTIDE; DER P 2 PEPTIDE; DNA VACCINE; FEL D 1 PEPTIDE; GAMMA INTERFERON; HISTAMINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G4; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; LEP D 2 PEPTIDE; PAM3CSK4; PEPTIDE; PHOSPHOLIPASE A2; PLACEBO; RECOMBINANT CYTOKINE; TOLL LIKE RECEPTOR 9; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLERGIC DISEASE; ARTICLE; ASTHMA; BEE STING; CELL ACTIVATION; CELL PROLIFERATION; CHEST TIGHTNESS; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ERYTHEMA; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; META ANALYSIS (TOPIC); NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROTEIN EXPRESSION; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT ALLERGY; SINGLE DRUG DOSE; T LYMPHOCYTE; VIRUS INFECTION;

ALLERGENS; ANTIGEN-PRESENTING CELLS; CYTOKINES; DRUG CARRIERS; EPITOPES, T-LYMPHOCYTE; HUMANS; HYPERSENSITIVITY; IMMUNOTHERAPY; LIGANDS; PEPTIDES; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH2 CELLS; VACCINES, DNA;

EID: 84884228811     PISSN: 18715230     EISSN: 1875614X     Source Type: Journal    
DOI: 10.2174/18715230113129990011     Document Type: Article

References (311)

1. Bousquet, J.; Lockey, R.; Malling, H. J. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J. Allergy. Clin. Immunol., 1998, 102 (4 Pt 1), 558-562.
2. Alvarez-Cuesta, E.; Bousquet, J.; Canonica, G. W.; Durham, S. R.; Malling, H. J.; Valovirta, E. Standards for practical allergenspecific immunotherapy. Allergy, 2006, 61 Suppl 82 1-20.
3. Rolland, J.; O'Hehir, R. Immunotherapy of allergy: anergy, deletion, and immune deviation. Curr. Opin. Immunol., 1998, 10 (6), 640-645.
4. Jutel, M.; Akdis, M.; Budak, F.; Aebischer-Casaulta, C.; Wrzyszcz, M.; Blaser, K.; Akdis, C. A. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur. J. Immunol., 2003, 33 (5), 1205-1214.
5. Larche, M. Inhibition of human T-cell responses by allergen peptides. Immunology, 2001, 104 (4), 377-382.
6. Rolland, J. M.; Gardner, L. M.; O'Hehir, R. E. Allergen-related approaches to immunotherapy. Pharmacol. Ther., 2009, 121 (3), 273-284.
7. Larche, M; Immunoregulation by targeting T cells in the treatment of allergy and asthma. Curr. Opin. Immunol., 2006, 18 (6), 745-750.
8. Bousquet, J.; Lockey, R. F.; Malling, H. J. WHO Position Paper. Allergen immunotherapy: theraputic vaccines for allergic disease. Allergy, 1998, 53 (Supp.) (44), 1-42.
9. Tovey, E. R.; Chapman, M. D.; Wells, C. W.; Platts-Mills, T. A. The distribution of dust mite allergen in the houses of patients with asthma. Am. Rev.Respir. Dis., 1981, 124 (5), 630-635.
10. Constant, S. L.; Bottomly, K. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu. Rev. Immunol., 1997, 15, 297-322.
11. Secrist, H.; DeKruyff, R. H.; Umetsu, D. T. Interleukin 4 production by CD4+ T cells from allergic individuals is modulated by antigen concentration and antigen-presenting cell type. J. Exp. Med., 1995, 181 (3), 1081-1089.
12. Sakai, K.; Yokoyama, A.; Kohno, N.; Hiwada, K. Effect of different sensitizing doses of antigen in a murine model of atopic asthma. Clin. Exp. Immunol., 1999, 118 (1), 9-15.
13. Carballido, J. M.; Faith, A.; Carballido-Perrig, N.; Blaser, K. The intensity of T cell receptor engagement determines the cytokine pattern of human allergen-specific T helper cells. Eur. J. Immunol., 1997, 27 (2), 515-521.
14. Grakoui, A.; Donermeyer, D. L.; Kanagawa, O.; Murphy, K. M.; Allen, P. M. TCR-independent pathways mediate the effects of antigen dose and altered peptide ligands on Th cell polarization. J. Immunol., 1999, 162 (4), 1923-1930.
15. Gardner, L. M.; O'Hehir, R. E.; Rolland, J. M. High dose allergen stimulation of T cells from house dust mite-allergic subjects induces expansion of IFN-gamma+ T Cells, apoptosis of CD4+IL-4+ T cells and T cell anergy. Int. Arch. Allergy Immunol., 2004, 133 (1), 1-13.
16. O'Hehir, R. E.; Yssel, H.; Verma, S.; de Vries, J. E.; Spits, H.; Lamb, J. R. Clonal analysis of differential lymphokine production in peptide and superantigen induced T cell anergy. Int. Immunol., 1991, 3 (8), 819-826.
17. Meiler, F.; Zumkehr, J.; Klunker, S.; Ruckert, B.; Akdis, C. A.; Akdis, M. In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. J. Exp. Med., 2008, 205 (12), 2887-2898.
18. Chapman, M. D.; Pomes, A.; Breiteneder, H.; Ferreira, F. Nomenclature and structural biology of allergens. J. Allergy Clin. Immunol., 2007, 119 (2), 414-420.
19. Stewart, G. A.; Robinson, C. The immunobiology of allergenic peptidases. Clin. Exp. Allergy, 2003, 33 (1), 3-6.
20. Wan, H.; Winton, H. L.; Soeller, C.; Tovey, E. R.; Gruenert, D. C.; Thompson, P. J.; Stewart, G. A.; Taylor, G. W.; Garrod, D. R.; Cannell, M. B.; Robinson, C. Der p 1 facilitates transepithelial allergen delivery by disruption of tight junctions. J. Clin. Invest., 1999, 104 (1), 123-133.
21. Ghaemmaghami, A. M.; Gough, L.; Sewell, H. F.; Shakib, F. The proteolytic activity of the major dust mite allergen Der p 1 conditions dendritic cells to produce less interleukin-12: allergen-induced Th2 bias determined at the dendritic cell level. Clin. Exp.Allergy, 2002, 32 (10), 1468-1475.
22. Ghaemmaghami, A. M.; Robins, A.; Gough, L.; Sewell, H. F.; Shakib, F. Human T cell subset commitment determined by the intrinsic property of antigen: the proteolytic activity of the major mite allergen Der p 1 conditions T cells to produce more IL-4 and less IFN-gamma. Eur. J. Immunol., 2001, 31 (4), 1211-1216.
23. Ghaemmaghami, A. M.; Shakib, F. Human T cells that have been conditioned by the proteolytic activity of the major dust mite allergen Der p 1 trigger enhanced immunoglobulin E synthesis by B cells. Clin. Exp. Allergy, 2002, 32 (5), 728-732.
24. Machado, D. C.; Horton, D.; Harrop, R.; Peachell, P. T.; Helm, B. A. Potential allergens stimulate the release of mediators of the allergic response from cells of mast cell lineage in the absence of sensitization with antigen-specific IgE. Eur. J. Immunol., 1996, 26 (12), 2972-2980.
25. Schulz, O.; Sewell, H. F.; Shakib, F. Proteolytic cleavage of CD25, the alpha subunit of the human T cell interleukin 2 receptor, by Der p 1, a major mite allergen with cysteine protease activity. J. Exp.Med., 1998, 187 (2), 271-275.
26. Schulz, O.; Laing, P.; Sewell, H. F.; Shakib, F. Der p I, a major allergen of the house dust mite, proteolytically cleaves the lowaffinity receptor for human IgE (CD23). Eur. J. Immunol., 1995, 25 (11), 3191-3194.
27. Hewitt, C. R.; Brown, A. P.; Hart, B. J.; Pritchard, D. I. A major house dust mite allergen disrupts the immunoglobulin E network by selectively cleaving CD23: innate protection by antiproteases. J. Exp. Med., 1995, 182 (5), 1537-1544.
28. Gough, L.; Campbell, E.; Bayley, D.; Van Heeke, G.; Shakib, F. Proteolytic activity of the house dust mite allergen Der p 1 enhances allergenicity in a mouse inhalation model. Clin. Exp. Allergy, 2003, 33 (8), 1159-1163.
29. Comoy, E. E.; Pestel, J.; Duez, C.; Stewart, G. A.; Vendeville, C.; Fournier, C.; Finkelman, F.; Capron, A.; Thyphronitis, G. The house dust mite allergen, Dermatophagoides pteronyssinus, promotes type 2 responses by modulating the balance between IL-4 and IFN-gamma. J. Immunol., 1998, 160 (5), 2456-2462.
30. Asokananthan, N.; Graham, P. T.; Stewart, D. J.; Bakker, A. J.; Eidne, K. A.; Thompson, P. J.; Stewart, G. A. House dust mite allergens induce proinflammatory cytokines from respiratory epithelial cells: the cysteine protease allergen, Der p 1, activates proteaseactivated receptor (PAR)-2 and inactivates PAR-1. J. Immunol., 2002, 169 (8), 4572-4578.
31. Chen, J. C.; Chuang, J. G.; Su, Y. Y.; Chiang, B. L.; Lin, Y. S.; Chow, L. P. The protease allergen Pen c 13 induces allergic airway inflammation and changes in epithelial barrier integrity and function in a murine model. J. Biol. Chem., 2011, 286 (30), 26667-26679.
32. Dudler, T.; Machado, D. C.; Kolbe, L.; Annand, R. R.; Rhodes, N.; Gelb, M. H.; Koelsch, K.; Suter, M.; Helm, B. A. A link between catalytic activity, IgE-independent mast cell activation, and allergenicity of bee venom phospholipase A2. J. Immunol., 1995, 155 (5), 2605-2613.
33. Okano, M.; Kino, K.; Takishita, T.; Hattori, H.; Ogawa, T.; Yoshino, T.; Yokoyama, M.; Nishizaki, K. Roles of carbohydrates on Cry j 1, the major allergen of Japanese cedar pollen, in specific T-cell responses. J. Allergy Clin. Immunol., 2001, 108 (1), 101-108.
34. Buentke, E.; Zargari, A.; Heffler, L. C.; Avila-Carino, J.; Savolainen, J.; Scheynius, A. Uptake of the yeast Malassezia furfur and its allergenic components by human immature CD1a+ dendritic cells. Clin. Exp. Allergy, 2000, 30 (12), 1759-1770.
35. Deslee Gt, G.; Hammad, H.; Angyalosi, G.; Tillie-Leblond, I.; Mantovani, A.; Tonnel, A. B.; Pestel, J. Involvement of the mannose receptor in the uptake of der p 1, a major mite allergen, by human dendritic cells. J. Allergy Clin. Immunol., 2002, 110 (5), 763-770.
36. Royer, P. J.; Emara, M.; Yang, C.; Al-Ghouleh, A.; Tighe, P.; Jones, N.; Sewell, H. F.; Shakib, F.; Martinez-Pomares, L.; Ghaemmaghami, A. M. The mannose receptor mediates the uptake of diverse native allergens by dendritic cells and determines allergen-induced T cell polarization through modulation of IDO activity. J. Immunol., 2010, 185 (3), 1522-1531.
37. Al-Ghouleh, A.; Johal, R.; Sharquie, I. K.; Emara, M.; Harrington, H.; Shakib, F.; Ghaemmaghami, A. M. The glycosylation pattern of common allergens: the recognition and uptake of Der p 1 by epithelial and dendritic cells is carbohydrate dependent. PLoS One, 2012, 7 (3), e33929.
38. Akdis, C. A.; Blesken, T.; Wymann, D.; Akdis, M.; Blaser, K. Differential regulation of human T cell cytokine patterns and IgE and IgG4 responses by conformational antigen variants. Eur. J. Immunol., 1998, 28 (3), 914-925.
39. van der Heijden, F. L.; Joost van Neerven, R. J.; van Katwijk, M.; Bos, J. D.; Kapsenberg, M. L. Serum-IgE-facilitated allergen presentation in atopic disease. J. Immunol., 1993, 150 (8 Pt 1), 3643-3650.
40. van Neerven, R. J.; Wikborg, T.; Lund, G.; Jacobsen, B.; Brinch-Nielsen, A.; Arnved, J.; Ipsen, H. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation. J. Immunol., 1999, 163 (5), 2944-2952.
41. Wachholz, P. A.; Soni, N. K.; Till, S. J.; Durham, S. R. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J. Allergy Clin. Immunol., 2003, 112 (5), 915-922.
42. Nouri-Aria, K. T.; Wachholz, P. A.; Francis, J. N.; Jacobson, M. R.; Walker, S. M.; Wilcock, L. K.; Staple, S. Q.; Aalberse, R. C.; Till, S. J.; Durham, S. R. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J. Immunol., 2004, 172 (5), 3252-3259.
43. Steinman, R. M.; Banchereau, J. Taking dendritic cells into medicine. Nature, 2007, 449 (7161), 419-426.
44. Lombardi, V.; Van Overtvelt, L.; Horiot, S.; Moingeon, P. Human dendritic cells stimulated via TLR7 and/or TLR8 induce the sequential production of Il-10, IFN-gamma, and IL-17A by naive CD4+ T cells. J. Immunol., 2009, 182 (6), 3372-3379.
45. Holt, P. G.; Schon-Hegrad, M. A.; Oliver, J.; Holt, B. J.; McMenamin, P. G. A contiguous network of dendritic antigenpresenting cells within the respiratory epithelium. Int. Arch. Allergy Appl. Immunol., 1990, 91 (2), 155-159.
46. Stumbles, P. A.; Thomas, J. A.; Pimm, C. L.; Lee, P. T.; Venaille, T. J.; Proksch, S.; Holt, P. G. Resting respiratory tract dendritic cells preferentially stimulate T helper cell type 2 (Th2) responses and require obligatory cytokine signals for induction of Th1 immunity. J. Exp. Med., 1998, 188 (11), 2019-2031.
47. Jonuleit, H.; Schmitt, E.; Schuler, G.; Knop, J.; Enk, A. H. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J. Exp. Med., 2000, 192 (9), 1213-1222.
48. Rissoan, M. C.; Soumelis, V.; Kadowaki, N.; Grouard, G.; Briere, F.; de Waal Malefyt, R.; Liu, Y. J. Reciprocal control of T helper cell and dendritic cell differentiation. Science, 1999, 283 (5405), 1183-1186.
49. Ito, T.; Yang, M.; Wang, Y. H.; Lande, R.; Gregorio, J.; Perng, O. A.; Qin, X. F.; Liu, Y. J.; Gilliet, M. Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand. J. Exp. Med., 2007, 204 (1), 105-115.
50. McGuirk, P.; McCann, C.; Mills, K. H. Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussis. J. Exp. Med., 2002, 195 (2), 221-231.
51. Urry, Z.; Xystrakis, E.; Richards, D. F.; McDonald, J.; Sattar, Z.; Cousins, D. J.; Corrigan, C. J.; Hickman, E.; Brown, Z.; Hawrylowicz, C. M. Ligation of TLR9 induced on human IL-10-secreting Tregs by 1alpha,25-dihydroxyvitamin D3 abrogates regulatory function. J. Clin. Invest., 2009, 119 (2), 387-398.
52. Mucida, D.; Park, Y.; Kim, G.; Turovskaya, O.; Scott, I.; Kronenberg, M.; Cheroutre, H. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science, 2007, 317 (5835), 256-260.
53. Darrasse-Jeze, G.; Deroubaix, S.; Mouquet, H.; Victora, G. D.; Eisenreich, T.; Yao, K. H.; Masilamani, R. F.; Dustin, M. L.; Rudensky, A.; Liu, K.; Nussenzweig, M. C. Feedback control of regulatory T cell homeostasis by dendritic cells in vivo. J. Exp. Med., 2009, 206 (9), 1853-1862.
54. Taylor, A.; Akdis, M.; Joss, A.; Akkoc, T.; Wenig, R.; Colonna, M.; Daigle, I.; Flory, E.; Blaser, K.; Akdis, C. A. IL-10 inhibits CD28 and ICOS costimulations of T cells via src homology 2 domain-containing protein tyrosine phosphatase 1. J. Allergy Clin Immunol., 2007, 120 (1), 76-83.
55. Pulendran, B.; Tang, H.; Manicassamy, S. Programming dendritic cells to induce T(H)2 and tolerogenic responses. Nat. Immunol., 2010, 11 (8), 647-655.
56. Malynn, B. A.; Romeo, D. T.; Wortis, H. H. Antigen-specific B cells efficiently present low doses of antigen for induction of T cell proliferation. J. Immunol., 1985, 135 (2), 980-988.
57. DeKruyff, R. H.; Fang, Y.; Umetsu, D. T. IL-4 synthesis by in vivo primed keyhole limpet hemocyanin-specific CD4+ T cells. I. Influence of antigen concentration and antigen-presenting cell type. J. Immunol., 1992, 149 (11), 3468-3476.
58. Macaulay, A. E.; DeKruyff, R. H.; Goodnow, C. C.; Umetsu, D. T. Antigen-specific B cells preferentially induce CD4+ T cells to produce IL-4. J. Immunol., 1997, 158 (9), 4171-4179.
59. Skok, J.; Poudrier, J.; Gray, D. Dendritic cell-derived IL-12 promotes B cell induction of Th2 differentiation: a feedback regulation of Th1 development. J. Immunol., 1999, 163 (8), 4284-4291.
60. Keane-Myers, A.; Gause, W. C.; Linsley, P. S.; Chen, S. J.; Wills-Karp, M. B7-CD28/CTLA-4 costimulatory pathways are required for the development of T helper cell 2-mediated allergic airway responses to inhaled antigens. J. Immunol., 1997, 158 (5), 2042-2049.
61. Krinzman, S. J.; De Sanctis, G. T.; Cernadas, M.; Mark, D.; Wang, Y.; Listman, J.; Kobzik, L.; Donovan, C.; Nassr, K.; Katona, I.; Christiani, D. C.; Perkins, D. L.; Finn, P. W. Inhibition of T cell costimulation abrogates airway hyperresponsiveness in a murine model. J. Clin. Invest., 1996, 98 (12), 2693-2699.
62. Kasai, M.; Kumano, K.; Kurasawa, K.; Nakao, A.; Saito, Y.; Iwamoto, I. Blockade of CD28/B7 interaction suppresses allergic eosinophilic inflammation in mice. Int. Arch. Allergy Immunol., 1998, 117 Suppl 1 14-19.
63. Burr, J. S.; Kimzey, S. L.; Randolph, D. R.; Green, J. M. CD28 and CTLA4 coordinately regulate airway inflammatory cell recruitment and T-helper cell differentiation after inhaled allergen. Am. J. Respir. Cell Mol. Biol., 2001, 24 (5), 563-568.
64. Tsuyuki, S.; Tsuyuki, J.; Einsle, K.; Kopf, M.; Coyle, A. J. Costimulation through B7-2 (CD86) is required for the induction of a lung mucosal T helper cell 2 (TH2) immune response and altered airway responsiveness. J. Exp. Med., 1997, 185 (9), 1671-1679.
65. Mark, D. A.; Donovan, C. E.; De Sanctis, G. T.; Krinzman, S. J.; Kobzik, L.; Linsley, P. S.; Sayegh, M. H.; Lederer, J.; Perkins, D. L.; Finn, P. W. Both CD80 and CD86 co-stimulatory molecules regulate allergic pulmonary inflammation. Int. Immunol., 1998, 10 (11), 1647-1655.
66. Van Neerven, R. J.; Van de Pol, M. M.; Van der Zee, J. S.; Stiekema, F. E.; De Boer, M.; Kapsenberg, M. L. Requirement of CD28-CD86 costimulation for allergen-specific T cell proliferation and cytokine expression. Clin. Exp. Allergy, 1998, 28 (7), 808-816.
67. Larche, M.; Till, S. J.; Haselden, B. M.; North, J.; Barkans, J.; Corrigan, C. J.; Kay, A. B.; Robinson, D. S. Costimulation through CD86 is involved in airway antigen-presenting cell and T cell responses to allergen in atopic asthmatics. J. Immunol., 1998, 161 (11), 6375-6382.
68. Jaffar, Z. H.; Stanciu, L.; Pandit, A.; Lordan, J.; Holgate, S. T.; Roberts, K. Essential role for both CD80 and CD86 costimulation, but not CD40 interactions, in allergen-induced Th2 cytokine production from asthmatic bronchial tissue: role for alphabeta, but not gammadelta,T cells. J. Immunol., 1999, 163 (11), 6283-6291.
69. Chen, Y. Q.; Shi, H. Z. CD28/CTLA-4--CD80/CD86 and ICOS--B7RP-1 costimulatory pathway in bronchial asthma. Allergy, 2006, 61 (1), 15-26.
70. Sharpe, A. H.; Freeman, G. J. The B7-CD28 superfamily. Nat. Rev. Immunol., 2002, 2 (2), 116-126.
71. Tesciuba, A. G.; Subudhi, S.; Rother, R. P.; Faas, S. J.; Frantz, A. M.; Elliot, D.; Weinstock, J.; Matis, L. A.; Bluestone, J. A.; Sperling, A. I. Inducible costimulator regulates Th2-mediated inflammation, but not Th2 differentiation, in a model of allergic airway disease. J. Immunol., 2001, 167 (4), 1996-2003.
72. Gonzalo, J. A.; Tian, J.; Delaney, T.; Corcoran, J.; Rottman, J. B.; Lora, J.; Al-garawi, A.; Kroczek, R.; Gutierrez-Ramos, J. C.; Coyle, A. J. ICOS is critical for T helper cell-mediated lung mucosal inflammatory responses. Nat. Immunol., 2001, 2 (7), 597-604.
73. Watanabe, M.; Watanabe, S.; Hara, Y.; Harada, Y.; Kubo, M.; Tanabe, K.; Toma, H.; Abe, R. ICOS-mediated costimulation on Th2 differentiation is achieved by the enhancement of IL-4 receptor-mediated signaling. J. Immunol., 2005, 174 (4), 1989-1996.
74. Nurieva, R. I.; Duong, J.; Kishikawa, H.; Dianzani, U.; Rojo, J. M.; Ho, I.; Flavell, R. A.; Dong, C. Transcriptional regulation of th2 differentiation by inducible costimulator. Immunity, 2003, 18 (6), 801-811.
75. Salomon, B.; Bluestone, J. A. LFA-1 interaction with ICAM-1 and ICAM-2 regulates Th2 cytokine production. J. Immunol., 1998, 161 (10), 5138-5142.
76. Luksch, C. R.; Winqvist, O.; Ozaki, M. E.; Karlsson, L.; Jackson, M. R.; Peterson, P. A.; Webb, S. R. Intercellular adhesion molecule-1 inhibits interleukin 4 production by naive T cells. Proc. Natl. Acad. Sci. USA, 1999, 96 (6), 3023-3028.
77. Ohshima, Y.; Yang, L. P.; Uchiyama, T.; Tanaka, Y.; Baum, P.; Sergerie, M.; Hermann, P.; Delespesse, G. OX40 costimulation enhances interleukin-4 (IL-4) expression at priming and promotes the differentiation of naive human CD4(+) T cells into high IL-4-producing effectors. Blood, 1998, 92 (9), 3338-3345.
78. Flynn, S.; Toellner, K. M.; Raykundalia, C.; Goodall, M.; Lane, P. CD4 T cell cytokine differentiation: the B cell activation molecule, OX40 ligand, instructs CD4 T cells to express interleukin 4 and upregulates expression of the chemokine receptor, Blr-1. J. Exp. Med., 1998, 188 (2), 297-304.
79. Ito, T.; Wang, Y. H.; Duramad, O.; Hori, T.; Delespesse, G. J.; Watanabe, N.; Qin, F. X.; Yao, Z.; Cao, W.; Liu, Y. J. TSLPactivated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J. Exp. Med., 2005, 202 (9), 1213-1223.
80. Rogers, P. R.; Croft, M. CD28, Ox-40, LFA-1, and CD4 modulation of Th1/Th2 differentiation is directly dependent on the dose of antigen. J. Immunol., 2000, 164 (6), 2955-2963.
81. Siddiqui, S.; Mistry, V.; Doe, C.; Stinson, S.; Foster, M.; Brightling, C. Airway wall expression of OX40/OX40L and interleukin-4 in asthma. Chest, 2010, 137 (4), 797-804.
82. Chen, X. X., Oppenheim, J.J. Resolving the identity myth: Key markers of functional CD4+FoxP3+ regulatory T cells. International Immunopharmacology, 2011, 11 1489-1496.
83. Schmetterer, K. G.; Neunkirchner, A.; Pickl, W. F. Naturally occurring regulatory T cells: markers, mechanisms, and manipulation. FASEB J., 2012, 26 (6), 2253-2276.
84. Konya, C.; Goronzy, J. J.; Weyand, C. M. Treating autoimmune disease by targeting CD8(+) T suppressor cells. Exp. Opin. Biol. Ther., 2009, 9 (8), 951-965.
85. Filaci, G.; Fenoglio, D.; Indiveri, F. CD8(+) T regulatory/suppressor cells and their relationships with autoreactivity and autoimmunity. Autoimmunity, 2011, 44 (1), 51-57.
86. Kapp, J. A.; Bucy, R. P. CD8+ suppressor T cells resurrected. Hum. Immunol., 2008, 69 (11), 715-720.
87. Rolland, J. M.; Gardner, L. M.; O'Hehir, R. E. Functional regulatory T cells and allergen immunotherapy. Curr. Opin. Allergy Clin. Immunol., 2010, 10 (6), 559-566.
88. McMurchy, A. N.; Levings, M. K. Suppression assays with human T regulatory cells: a technical guide. Eur. J. Immunol., 2012, 42 (1), 27-34.
89. Brusko, T. M.; Hulme, M. A.; Myhr, C. B.; Haller, M. J.; Atkinson, M. A. Assessing the in vitro suppressive capacity of regulatory T cells. Immunol. Invest., 2007, 36 (5-6), 607-628.
90. Roncarolo, M. G.; Gregori, S.; Battaglia, M.; Bacchetta, R.; Fleischhauer, K.; Levings, M. K. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol. Rev., 2006, 212 28-50.
91. Coombes, J. L.; Siddiqui, K. R.; Arancibia-Carcamo, C. V.; Hall, J.; Sun, C. M.; Belkaid, Y.; Powrie, F. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J. Exp. Med., 2007, 204 (8), 1757-1764.
92. Li, M. O.; Sanjabi, S.; Flavell, R. A. Transforming growth factorbeta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and-independent mechanisms. Immunity, 2006, 25 (3), 455-471.
93. Vignali, D. A.; Collison, L. W.; Workman, C. J. How regulatory T cells work. Nat. Rev. Immunol., 2008, 8 (7), 523-532.
94. McMenamin, C.; Holt, P. G. The natural immune response to inhaled soluble protein antigens involves major histocompatibility complex (MHC) class I-restricted CD8+ T cell-mediated but MHC class II-restricted CD4+ T cell-dependent immune deviation resulting in selective suppression of immunoglobulin E production. J. Exp. Med., 1993, 178 (3), 889-899.
95. Renz, H.; Lack, G.; Saloga, J.; Schwinzer, R.; Bradley, K.; Loader, J.; Kupfer, A.; Larsen, G. L.; Gelfand, E. W. Inhibition of IgE production and normalization of airways responsiveness by sensitized CD8 T cells in a mouse model of allergen-induced sensitization. J. Immunol., 1994, 152 (1), 351-360.
96. Holmes, B. J.; MacAry, P. A.; Noble, A.; Kemeny, D. M. Antigenspecific CD8+ T cells inhibit IgE responses and interleukin-4 production by CD4+ T cells. Eur. J. Immunol., 1997, 27 (10), 2657-2665.
97. Betts, R. J.; Kemeny, D. M. CD8+ T cells in asthma: friend or foe? Pharmacol. Ther., 2009, 121 (2), 123-131.
98. Akdis, C. A.; Akdis, M. Mechanisms and treatment of allergic disease in the big picture of regulatory T cells. J. Allergy Clin. Immunol., 2009, 123 (4), 735-746quiz 747-738.
99. Anderson, A. E.; Mackerness, K. J.; Aizen, M.; Carr, V. A.; Nguyen, D.; Du Pre, F.; Durham, S. R.; Robinson, D. S. Seasonal changes in suppressive capacity of CD4+ CD25+ T cells from patients with hayfever are allergen-specific and may result in part from expansion of effector T cells among the CD25+ population. Clin. Exp. Allergy, 2009, 39 (11), 1693-1699.
100. Akdis, M.; Verhagen, J.; Taylor, A.; Karamloo, F.; Karagiannidis, C.; Crameri, R.; Thunberg, S.; Deniz, G.; Valenta, R.; Fiebig, H.; Kegel, C.; Disch, R.; Schmidt-Weber, C. B.; Blaser, K.; Akdis, C. A. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J. Exp. Med., 2004, 199 (11), 1567-1575.
101. Grindebacke, H.; Wing, K.; Andersson, A. C.; Suri-Payer, E.; Rak, S.; Rudin, A. Defective suppression of Th2 cytokines by CD4CD25 regulatory T cells in birch allergics during birch pollen season. Clin. Exp. Allergy, 2004, 34 (9), 1364-1372.
102. Thunberg, S.; Akdis, M.; Akdis, C. A.; Gronneberg, R.; Malmstrom, V.; Trollmo, C.; van Hage, M.; Gafvelin, G. Immune regulation by CD4+CD25+ T cells and interleukin-10 in birch pollenallergic patients and non-allergic controls. Clin. Exp. Allergy, 2007, 37 (8), 1127-1136.
103. Ling, E. M.; Smith, T.; Nguyen, X. D.; Pridgeon, C.; Dallman, M.; Arbery, J.; Carr, V. A.; Robinson, D. S. Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet, 2004, 363 (9409), 608-615.
104. Bellinghausen, I.; Konig, B.; Bottcher, I.; Knop, J.; Saloga, J. Regulatory activity of human CD4 CD25 T cells depends on allergen concentration, type of allergen and atopy status of the donor. Immunology, 2005, 116 (1), 103-111.
105. Bellinghausen, I.; Klostermann, B.; Knop, J.; Saloga, J. Human CD4+CD25+ T cells derived from the majority of atopic donors are able to suppress TH1 and TH2 cytokine production. J. Allergy Clin. Immunol., 2003, 111 (4), 862-868.
106. Mittag, D.; Scholzen, A.; Varese, N.; Baxter, L.; Paukovics, G.; Harrison, L. C.; Rolland, J. M.; O'Hehir, R. E. The effector T cell response to ryegrass pollen is counterregulated by simultaneous induction of regulatory T cells. J. Immunol., 2010, 184 (9), 4708-4716.
107. Akdis, M.; Akdis, C. A. Therapeutic manipulation of immune tolerance in allergic disease. Nat. Rev. Drug Discov., 2009, 8 (8), 645-660.
108. Verhoef, A.; Alexander, C.; Kay, A. B.; Larche, M. T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity. PLoS Med., 2005, 2 (3), e78.
109. Gardner, L. M.; Thien, F. C.; Douglass, J. A.; Rolland, J. M.; O'Hehir, R. E. Induction of T 'regulatory' cells by standardized house dust mite immunotherapy: an increase in CD4+ CD25+ in terleukin-10+ T cells expressing peripheral tissue trafficking markers. Clin. Exp. Allergy, 2004, 34 (8), 1209-1219.
110. Francis, J. N.; Till, S. J.; Durham, S. R. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin. Immunol., 2003, 111 (6), 1255-1261.
111. Akdis, C. A.; Blaser, K. IL-10-induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: two key steps in specific immunotherapy. FASEB J., 1999, 13 (6), 603-609.
112. Akdis, C. A.; Blesken, T.; Akdis, M.; Wuthrich, B.; Blaser, K. Role of interleukin 10 in specific immunotherapy. J. Clin. Invest., 1998, 102 (1), 98-106.
113. Oldfield, W. L.; Larche, M.; Kay, A. B. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet, 2002, 360 (9326), 47-53.
114. Mobs, C.; Slotosch, C.; Loffler, H.; Jakob, T.; Hertl, M.; Pfutzner, W. Birch pollen immunotherapy leads to differential induction of regulatory T cells and delayed helper T cell immune deviation. J. Immunol., 2010, 184 (4), 2194-2203.
115. Grindebacke, H.; Larsson, P.; Wing, K.; Rak, S.; Rudin, A. Specific immunotherapy to birch allergen does not enhance suppression of Th2 cells by CD4(+)CD25(+) regulatory T cells during pollen season. J. Clin. Immunol., 2009, 29 (6), 752-760.
116. Wei, W.; Liu, Y.; Wang, Y.; Zhao, Y.; He, J.; Li, X.; Shen, K. Induction of CD4+CD25+Foxp3+IL-10+ T cells in HDM-allergic asthmatic children with or without SIT. Int. Arch. Allergy Immunol., 2010, 153 (1), 19-26.
117. Bohle, B.; Kinaciyan, T.; Gerstmayr, M.; Radakovics, A.; Jahn-Schmid, B.; Ebner, C. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J. Allergy Clin. Immunol., 2007, 120 (3), 707-713.
118. Yamanaka, K.; Yuta, A.; Kakeda, M.; Sasaki, R.; Kitagawa, H.; Gabazza, E. C.; Okubo, K.; Kurokawa, I.; Mizutani, H. Induction of IL-10-producing regulatory T cells with TCR diversity by epitope-specific immunotherapy in pollinosis. J. Allergy Clin. Immunol., 2009, 124 (4), 842-845.e847.
119. Jones, S. M.; Pons, L.; Roberts, J. L.; Scurlock, A. M.; Perry, T. T.; Kulis, M.; Shreffler, W. G.; Steele, P.; Henry, K. A.; Adair, M.; Francis, J. M.; Durham, S.; Vickery, B. P.; Zhong, X.; Burks, A. W. Clinical efficacy and immune regulation with peanut oral immunotherapy. J. Allergy Clin. Immunol., 2009, 124 (2), 292-300.300 e291-297.
120. Taylor, A.; Verhagen, J.; Blaser, K.; Akdis, M.; Akdis, C. A. Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: the role of T regulatory cells. Immunology, 2006, 117 (4), 433-442.
121. O'Hehir, R. E.; Gardner, L. M.; de Leon, M. P.; Hales, B. J.; Biondo, M.; Douglass, J. A.; Rolland, J. M.; Sandrini, A. House dust mite sublingual immunotherapy: the role for transforming growth factor-beta and functional regulatory T cells. Am. J. Respir. Crit. Care Med., 2009, 180 (10), 936-947.
122. Ciprandi, G.; De Amici, M.; Tosca, M. A.; Pistorio, A.; Marseglia, G. L. Sublingual immunotherapy affects specific antibody and TGF-beta serum levels in patients with allergic rhinitis. Int. J. Immunopathol. Pharmacol., 2009, 22 (4), 1089-1096.
123. Ciprandi, G.; De Amici, M.; Negrini, S.; Marseglia, G.; Tosca, M. A. TGF-beta and IL-17 serum levels and specific immunotherapy. Int. Immunopharmacol., 2009, 9 (10), 1247-1249.
124. Pilette, C.; Nouri-Aria, K. T.; Jacobson, M. R.; Wilcock, L. K.; Detry, B.; Walker, S. M.; Francis, J. N.; Durham, S. R. Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-beta expression. J. Immunol., 2007, 178 (7), 4658-4666.
125. Ajduk, J.; Marinic, I.; Aberle, N.; Rabatic, S.; Gagro, A. Effect of house dust mite immunotherapy on transforming growth factor beta1-producing T cells in asthmatic children. Ann. Allergy Asthma Immunol., 2008, 100 (4), 314-322.
126. Lou, W.; Wang, C.; Wang, Y.; Han, D.; Zhang, L. Responses of CD4(+) CD25(+) Foxp3(+) and IL-10-secreting type I T regulatory cells to cluster-specific immunotherapy for allergic rhinitis in children. Pediatr. Allergy Immunol., 2012, 23 (2), 140-149.
127. Gardner, L. M.; Spyroglou, L.; O'Hehir, R. E.; Rolland, J. M. Increased allergen concentration enhances IFN-gamma production by allergic donor T cells expressing a peripheral tissue trafficking phenotype. Allergy, 2004, 59 (12), 1308-1317.
128. Radulovic, S.; Jacobson, M. R.; Durham, S. R.; Nouri-Aria, K. T. Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J. Allergy Clin. Immunol., 2008, 121 (6), 1467-1472.1472 e1461.
129. Scadding, G. W.; Shamji, M. H.; Jacobson, M. R.; Lee, D. I.; Wilson, D.; Lima, M. T.; Pitkin, L.; Pilette, C.; Nouri-Aria, K.; Durham, S. R. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin. Exp. Allergy, 2010, 40 (4), 598-606.
130. Palomares, O.; Ruckert, B.; Jartti, T.; Kucuksezer, U. C.; Puhakka, T.; Gomez, E.; Fahrner, H. B.; Speiser, A.; Jung, A.; Kwok, W. W.; Kalogjera, L.; Akdis, M.; Akdis, C. A. Induction and maintenance of allergen-specific FOXP3+ Treg cells in human tonsils as potential first-line organs of oral tolerance. J. Allergy Clin. Immunol., 2012, 129 (2), 510-520. 520 e511-519.
131. Vita, R.; Zarebski, L.; Greenbaum, J. A.; Emami, H.; Hoof, I.; Salimi, N.; Damle, R.; Sette, A.; Peters, B. The immune epitope database 2.0. Nucleic Acids Res., 2010, 38 (Database issue), D854-862.
132. Vaughan, K.; Greenbaum, J.; Blythe, M.; Peters, B.; Sette, A. Meta-analysis of all immune epitope data in the Flavivirus genus: inventory of current immune epitope data status in the context of virus immunity and immunopathology. Viral. Immunol., 2010, 23 (3), 259-284.
133. Etto, T.; de Boer, C.; Prickett, S.; Gardner, L. M.; Voskamp, A.; Davies, J. M.; O'Hehir, R. E.; Rolland, J. M. Unique and crossreactive T cell epitope peptides of the major Bahia grass pollen allergen, Pas n 1. Int. Arch. Allergy Immunol., 2012, 159 (4), 355-366.
134. Glaspole, I. N.; de Leon, M. P.; Prickett, S. R.; O'Hehir, R. E.; Rolland, J. M. Clinical allergy to hazelnut and peanut: identification of T cell cross-reactive allergens. Int. Arch. Allergy Immunol., 2011, 155 (4), 345-354.
135. Jahn-Schmid, B.; Radakovics, A.; Luttkopf, D.; Scheurer, S.; Vieths, S.; Ebner, C.; Bohle, B. Bet v 1142-156 is the dominant Tcell epitope of the major birch pollen allergen and important for cross-reactivity with Bet v 1-related food allergens. J. Allergy Clin. Immunol., 2005, 116 (1), 213-219.
136. Sone, T.; Dairiki, K.; Morikubo, K.; Shimizu, K.; Tsunoo, H.; Mori, T.; Kino, K. Identification of human T cell epitopes in Japanese cypress pollen allergen, Cha o 1, elucidates the intrinsic mechanism of cross-allergenicity between Cha o 1 and Cry j 1, the major allergen of Japanese cedar pollen, at the T cell level. Clin. Exp. Allergy, 2005, 35 (5), 664-671.
137. Schenk, S.; Breiteneder, H.; Susani, M.; Najafian, N.; Laffer, S.; Duchene, M.; Valenta, R.; Fischer, G.; Scheiner, O.; Kraft, D. et al. T-cell epitopes of Phl p 1, major pollen allergen of timothy grass (Phleum pratense): evidence for crossreacting and noncrossreacting T-cell epitopes within grass group I allergens. J Allergy Clin. Immunol., 1995, 96 (6 Pt 1), 986-996.
138. Rudensky, A.; Preston-Hurlburt, P.; Hong, S. C.; Barlow, A.; Janeway, C. A., Jr. Sequence analysis of peptides bound to MHC class II molecules. Nature, 1991, 353 (6345), 622-627.
139. Sette, A.; Sidney, J. HLA supertypes and supermotifs: a functional perspective on HLA polymorphism. Curr. Opin. Immunol., 1998, 10 (4), 478-482.
140. Southwood, S.; Sidney, J.; Kondo, A.; del Guercio, M. F.; Appella, E.; Hoffman, S.; Kubo, R. T.; Chesnut, R. W.; Grey, H. M.; Sette, A. Several common HLA-DR types share largely overlapping peptide binding repertoires. J. Immunol., 1998, 160 (7), 3363-3373.
141. Sidney, J.; Peters, B.; Frahm, N.; Brander, C.; Sette, A. HLA class I supertypes: a revised and updated classification. BMC Immunol., 2008, 9 1.
142. Greenbaum, J.; Sidney, J.; Chung, J.; Brander, C.; Peters, B.; Sette, A. Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes. Immunogenetics, 2011, 63 (6), 325-335.
143. Larche, M. Of cats and men: immunodominance and the role of HLA-DP/DQ. Clin. Exp. Allergy, 2008, 38 (11), 1709-1711.
144. Texier, C.; Pouvelle, S.; Busson, M.; Herve, M.; Charron, D.; Menez, A.; Maillere, B. HLA-DR restricted peptide candidates for bee venom immunotherapy. J. Immunol., 2000, 164 (6), 3177-3184.
145. Bateman, E. A.; Ardern-Jones, M. R.; Ogg, G. S. Identification of an immunodominant region of Fel d 1 and characterization of constituent epitopes. Clin. Exp. Allergy, 2008, 38 (11), 1760-1768.
146. Crack, L. R.; Chan, H. W.; McPherson, T.; Ogg, G. S. Identification of an immunodominant region of the major house dust mite allergen Der p 2 presented by common human leucocyte antigen alleles. Clin. Exp. Dermatol., 2012, 37 (3), 266-276.
147. Prickett, S. R.; Voskamp, A. L.; Dacumos-Hill, A.; Symons, K.; Rolland, J. M.; O'Hehir, R. E. Ara h 2 peptides containing dominant CD4+ T-cell epitopes: candidates for a peanut allergy therapeutic. J. Allergy Clin. Immunol., 2011, 127 (3), 608-615. e601-605.
148. Ruiter, B.; Rozemuller, E. H.; van Dijk, A. J.; Garssen, J.; Bruijnzeel-Koomen, C. A.; Tilanus, M. G.; Knol, E. F.; van Hoffen, E. Role of human leucocyte antigen DQ in the presentation of T cell epitopes in the major cow's milk allergen alphas1-casein. Int. Arch. Allergy Immunol., 2007, 143 (2), 119-126.
149. Friedl-Hajek, R.; Spangfort, M. D.; Schou, C.; Breiteneder, H.; Yssel, H.; Joost van Neerven, R. J. Identification of a highly promiscuous and an HLA allele-specific T-cell epitope in the birch major allergen Bet v 1: HLA restriction, epitope mapping and TCR sequence comparisons. Clin. Exp. Allergy, 1999, 29 (4), 478-487.
150. Wurtzen, P.; Wissenbach, M.; Ipsen, H.; Bufe, A.; Arnved, J.; van Neerven, R. J. Highly heterogeneous Phl p 5-specific T cells from patients with allergic rhinitis differentially recognize recombinant Phl p 5 isoallergens. J. Allergy Clin. Immunol., 1999, 104 (1), 115-122.
151. Shinbara, M.; Kondo, N.; Agata, H.; Fukutomi, O.; Nishida, T.; Kobayashi, Y.; Orii, T. T cell proliferation restricted by HLA class II molecules in patients with hen's egg allergy. Exp. Clin. Immunogenet., 1995, 12 (2), 103-110.
152. Higgins, J. A.; Lamb, J. R.; Lake, R. A.; O'Hehir, R. E. Polyclonal and clonal analysis of human CD4+ T-lymphocyte responses to nut extracts. Immunology, 1995, 84 (1), 91-97.
153. Santambrogio, L.; Sato, A. K.; Carven, G. J.; Belyanskaya, S. L.; Strominger, J. L.; Stern, L. J. Extracellular antigen processing and presentation by immature dendritic cells. Proc. Natl. Acad Sci. USA., 1999, 96 (26), 15056-15061.
154. Moldaver, D.; Larche, M. Immunotherapy with peptides. Allergy, 2011, 66 (6), 784-791.
155. Hoyne, G. F.; O'Hehir, R. E.; Wraith, D. C.; Thomas, W. R.; Lamb, J. R. Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice. J. Exp. Med., 1993, 178 (5), 1783-1788.
156. Hoyne, G. F.; Jarnicki, A. G.; Thomas, W. R.; Lamb, J. R. Characterization of the specificity and duration of T cell tolerance to intranasally administered peptides in mice: a role for intramolecular epitope suppression. Int. Immunol., 1997, 9 (8), 1165-1173.
157. Briner, T. J.; Kuo, M. C.; Keating, K. M.; Rogers, B. L.; Greenstein, J. L. Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I. Proc. Natl. Acad. Sci.USA., 1993, 90 (16), 7608-7612.
158. Hirahara, K.; Saito, S.; Serizawa, N.; Sasaki, R.; Sakaguchi, M.; Inouye, S.; Taniguchi, Y.; Kaminogawa, S.; Shiraishi, A. Oral administration of a dominant T-cell determinant peptide inhibits allergen-specific TH1 and TH2 cell responses in Cry j 2-primed mice. J. Allergy Clin. Immunol., 1998, 102 (6 Pt 1), 961-967.
159. Astori, M.; von Garnier, C.; Kettner, A.; Dufour, N.; Corradin, G.; Spertini, F. Inducing tolerance by intranasal administration of long peptides in naive and primed CBA/J mice. J. Immunol., 2000, 165 (6), 3497-3505.
160. Murasugi, T.; Nakagami, Y.; Yoshitomi, T.; Hirahara, K.; Yamashita, M.; Taniguchi, Y.; Sakaguchi, M.; Ito, K. Oral administration of a T cell epitope inhibits symptoms and reactions of allergic rhinitis in Japanese cedar pollen allergen-sensitized mice. Eur. J. Pharmacol., 2005, 510 (1-2), 143-148.
161. Bauer, L.; Bohle, B.; Jahn-Schmid, B.; Wiedermann, U.; Daser, A.; Renz, H.; Kraft, D.; Ebner, C. Modulation of the allergic immune response in BALB/c mice by subcutaneous injection of high doses of the dominant T cell epitope from the major birch pollen allergen Bet v 1. Clin. Exp. Immunol., 1997, 107 (3), 536-541.
162. Yang, M.; Yang, C.; Mine, Y. Multiple T cell epitope peptides suppress allergic responses in an egg allergy mouse model by the elicitation of forkhead box transcription factor 3-and transforming growth factor-beta-associated mechanisms. Clin. Exp. Allergy, 2010, 40 (4), 668-678.
163. Rupa, P.; Mine, Y. Oral immunotherapy with immunodominant Tcell epitope peptides alleviates allergic reactions in a Balb/c mouse model of egg allergy. Allergy, 2012, 67 (1), 74-82.
164. Yoshitomi, T.; Nakagami, Y.; Hirahara, K.; Taniguchi, Y.; Sakaguchi, M.; Yamashita, M. Intraoral administration of a T-cell epitope peptide induces immunological tolerance in Cry j 2-sensitized mice. J. Pept. Sci., 2007, 13 (8), 499-503.
165. Marazuela, E. G.; Rodriguez, R.; Fernandez-Garcia, H.; Garcia, M. S.; Villalba, M.; Batanero, E. Intranasal immunization with a dominant T-cell epitope peptide of a major allergen of olive pollen prevents mice from sensitization to the whole allergen. Mol. Immunol., 2008, 45 (2), 438-445.
166. Campbell, J. D.; Buckland, K. F.; McMillan, S. J.; Kearley, J.; Oldfield, W. L.; Stern, L. J.; Gronlund, H.; van Hage, M.; Reynolds, C. J.; Boyton, R. J.; Cobbold, S. P.; Kay, A. B.; Altmann, D. M.; Lloyd, C. M.; Larche, M. Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression. J. Exp. Med., 2009, 206 (7), 1535-1547.
167. Takaiwa, F. Seed-based oral vaccines as allergen-specific immunotherapies. Hum. Vaccin., 2011, 7 (3), 357-366.
168. Takagi, H.; Hiroi, T.; Yang, L.; Tada, Y.; Yuki, Y.; Takamura, K.; Ishimitsu, R.; Kawauchi, H.; Kiyono, H.; Takaiwa, F. A rice-based edible vaccine expressing multiple T cell epitopes induces oral tolerance for inhibition of Th2-mediated IgE responses. Proc. Natl. Acad. Sci. USA., 2005, 102 (48), 17525-17530.
169. Suzuki, K.; Kaminuma, O.; Yang, L.; Takai, T.; Mori, A.; Umezu-Goto, M.; Ohtomo, T.; Ohmachi, Y.; Noda, Y.; Hirose, S.; Okumura, K.; Ogawa, H.; Takada, K.; Hirasawa, M.; Hiroi, T.; Takaiwa, F. Prevention of allergic asthma by vaccination with transgenic rice seed expressing mite allergen: induction of allergenspecific oral tolerance without bystander suppression. Plant Biotechnol J., 2011, 9 (9), 982-990.
170. Chen, K. W.; Focke-Tejkl, M.; Blatt, K.; Kneidinger, M.; Gieras, A.; Dall'Antonia, F.; Fae, I.; Fischer, G.; Keller, W.; Valent, P.; Valenta, R.; Vrtala, S. Carrier-bound nonallergenic Der p 2 peptides induce IgG antibodies blocking allergen-induced basophil activation in allergic patients. Allergy, 2012, 67 (5), 609-621.
171. Norman, P. S.; Ohman, J. L., Jr.; Long, A. A.; Creticos, P. S.; Gefter, M. A.; Shaked, Z.; Wood, R. A.; Eggleston, P. A.; Hafner, K. B.; Rao, P.; Lichtenstein, L. M.; Jones, N. H.; Nicodemus, C. F. Treatment of cat allergy with T-cell reactive peptides. Am. J. Respir Crit. Care. Med., 1996, 154 (6 Pt 1), 1623-1628.
172. Marcotte, G. V.; Braun, C. M.; Norman, P. S.; Nicodemus, C. F.; Kagey-Sobotka, A.; Lichtenstein, L. M.; Essayan, D. M. Effects of peptide therapy on ex vivo T-cell responses. J. Allerg Clin. Immunol., 1998, 101 (4 Pt 1), 506-513.
173. Pene, J.; Desroches, A.; Paradis, L.; Lebel, B.; Farce, M.; Nicodemus, C. F.; Yssel, H.; Bousquet, J. Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats. J. Allergy Clin. Immunol., 1998, 102 (4 Pt 1), 571-578.
174. Maguire, P.; Nicodemus, C.; Robinson, D.; Aaronson, D.; Umetsu, D. T. The safety and efficacy of ALLERVAX CAT in cat allergic patients. Clin. Immunol., 1999, 93 (3), 222-231.
175. Alexander, C.; Tarzi, M.; Larche, M.; Kay, A. B. The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects. Allergy, 2005, 60 (10), 1269-1274.
176. Alexander, C.; Ying, S.; A, B. K.; Larche, M. Fel d 1-derived T cell peptide therapy induces recruitment of CD4+ CD25+; CD4+ interferon-gamma+ T helper type 1 cells to sites of allergeninduced latephase skin reactions in cat-allergic subjects. Clin. Exp. Allergy., 2005, 35 (1), 52-58.
177. Smith, T. R.; Alexander, C.; Kay, A. B.; Larche, M.; Robinson, D. S. Cat allergen peptide immunotherapy reduces CD4(+) T cell responses to cat allergen but does not alter suppression by CD4(+) CD25(+) T cells: a double-blind placebo-controlled study. Allergy, 2004, 59 (10), 1097-1101.
178. Worm, M.; Lee, H. H.; Kleine-Tebbe, J.; Hafner, R. P.; Laidler, P.; Healey, D.; Buhot, C.; Verhoef, A.; Maillere, B.; Kay, A. B.; Larche, M. Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. J. Allergy Clin. Immunol., 2011, 127 (1), 89-97. 97 e81-14.
179. Muller, U.; Akdis, C. A.; Fricker, M.; Akdis, M.; Blesken, T.; Bettens, F.; Blaser, K. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific Tcell anergy in patients allergic to bee venom. J. Allergy. Clin Immunol., 1998, 101 (6 Pt 1), 747-754.
180. Tarzi, M.; Klunker, S.; Texier, C.; Verhoef, A.; Stapel, S. O.; Akdis, C. A.; Maillere, B.; Kay, A. B.; Larche, M. Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy. Clin. Exp. Allergy., 2006, 36 (4), 465-474.
181. Fellrath, J. M.; Kettner, A.; Dufour, N.; Frigerio, C.; Schneeberger, D.; Leimgruber, A.; Corradin, G.; Spertini, F. Allergen-specific Tcell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial. J. Allergy Clin. Immunol., 2003, 111 (4), 854-861.
182. Pipet, A.; Botturi, K.; Pinot, D.; Vervloet, D.; Magnan, A. Allergen-specific immunotherapy in allergic rhinitis and asthma. Mechanisms and proof of efficacy. Respir. Med., 2009, 103 (6), 800-812.
183. Nishimura, Y.; Chen, Y. Z.; Uemura, Y.; Tanaka, Y.; Tsukamoto, H.; Kanai, T.; Yokomizo, H.; Yun, C.; Matsuoka, T.; Irie, A.; Matsushita, S. Degenerate recognition and response of human CD4+ Th cell clones: implications for basic and applied immunology. Mol. Immunol., 2004, 40 (14-15), 1089-1094.
184. Sadegh-Nasseri, S.; Dalai, S. K.; Korb Ferris, L. C.; Mirshahidi, S. Suboptimal engagement of the T-cell receptor by a variety of peptide-MHC ligands triggers T-cell anergy. Immunology., 2010, 129 (1), 1-7.
185. Ikagawa, S.; Matsushita, S.; Chen, Y. Z.; Ishikawa, T.; Nishimura, Y. Single amino acid substitutions on a Japanese cedar pollen allergen (Cry j 1)-derived peptide induced alterations in human T cell responses and T cell receptor antagonism. J. Allergy Clin Immunol., 1996, 97 (1 Pt 1), 53-64.
186. De Palma, R.; Wu, S.; Sallusto, F.; Di Felice, G.; Martucci, P.; Geraci, D.; Colombo, P.; Troise, C.; Sacerdoti, G.; Nocera, A.; Gorski, J. Use of antagonist peptides to inhibit in vitro T cell responses to Par j1, the major allergen of Parietaria judaica pollen. J. Immunol., 1999, 162 (4), 1982-1987.
187. Fasler, S.; Aversa, G.; de Vries, J. E.; Yssel, H. Antagonistic peptides specifically inhibit proliferation, cytokine production, CD40L expression, and help for IgE synthesis by Der p 1-specific human T-cell clones. J. Allergy Clin Immunol., 1998, 101 (4 Pt 1), 521-530.
188. Tsitoura, D. C.; Verhoef, A.; Gelder, C. M.; O'Hehir, R. E.; Lamb, J. R. Altered T cell ligands derived from a major house dust mite allergen enhance IFN-gamma but not IL-4 production by human CD4+ T cells. J. Immunol., 1996, 157 (5), 2160-2165.
189. Matsuoka, T.; Kohrogi, H.; Ando, M.; Nishimura, Y.; Matsushita, S. Altered TCR ligands affect antigen-presenting cell responses: up-regulation of IL-12 by an analogue peptide. J. Immunol., 1996, 157 (11), 4837-4843.
190. Faith, A.; Akdis, C. A.; Akdis, M.; Joss, A.; Wymann, D.; Blaser, K. An altered peptide ligand specifically inhibits Th2 cytokine synthesis by abrogating TCR signaling. J. Immunol., 1999, 162 (3), 1836-1842.
191. Kim, J. R.; Irie, A.; Tsukamoto, H.; Nishimura, Y. A role of kinase inactive ZAP-70 in altered peptide ligand stimulated T cell activation. Biochem. Biophys. Res. Commun., 2006, 341 (1), 19-27.
192. Verhoef, A.; Lamb, J. R. Threshold signaling of human Th0 cells in activation and anergy: modulation of effector function by altered TCR ligand. J. Immunol., 2000, 164 (11), 6034-6040.
193. Kondo, M.; Kaneko, H.; Fukao, T.; Suzuki, K.; Sakaguchi, H.; Shinoda, S.; Kato, Z.; Matsui, E.; Teramoto, T.; Nakano, T.; Kondo, N. The response of bovine beta-lactoglobulin-specific Tcell clones to single amino acid substitution of T-cell core epitope. Pediatr. Allergy Immunol., 2008, 19 (7), 592-598.
194. Kinnunen, T.; Buhot, C.; Narvanen, A.; Rytkonen-Nissinen, M.; Saarelainen, S.; Pouvelle-Moratille, S.; Rautiainen, J.; Taivainen, A.; Maillere, B.; Mantyjarvi, R.; Virtanen, T. The immunodominant epitope of lipocalin allergen Bos d 2 is suboptimal for human T cells. Eur. J. Immunol., 2003, 33 (6), 1717-1726.
195. Kinnunen, T.; Jutila, K.; Kwok, W. W.; Rytkonen-Nissinen, M.; Immonen, A.; Saarelainen, S.; Narvanen, A.; Taivainen, A.; Virtanen, T. Potential of an altered peptide ligand of lipocalin allergen Bos d 2 for peptide immunotherapy. J. Allergy Clin Immunol., 2007, 119 (4), 965-972.
196. Katsara, M.; Minigo, G.; Plebanski, M.; Apostolopoulos, V. The good, the bad and the ugly: how altered peptide ligands modulate immunity. Expert. Opin. Biol. Ther., 2008, 8 (12), 1873-1884.
197. Marsh, D. G.; Lichtenstein, L. M.; Campbell, D. H. Studies on allergoids prepared from naturally occurring allergens. I. Assay of allergenicity and antigenicity of formalinized rye group I component. Immunology, 1970, 18 (5), 705-722.
198. Marsh, D. G.; Norman, P. S.; Roebber, M.; Lichtenstein, L. M. Studies on allergoids from naturally occurring allergens. III. Preparation of ragweed pollen allergoids by aldehyde modification in two steps. J. Allergy Clin. Immunol., 1981, 68 (6), 449-459.
199. Metzger, W. J.; Dorminey, H. C.; Richerson, H. B.; Weiler, J. M.; Donnelly, A.; Moran, D. Clinical and immunologic evaluation of glutaraldehyde-modified tyrosine-adsorbed short ragweed extract: a double-blind, placebo-controlled trial. J. Allergy Clin. Immunol., 1981, 68 (6), 442-448.
200. Norman, P. S.; Lichtenstein, L. M.; Kagey-Sobotka, A.; Marsh, D. G. Controlled evaluation of allergoid in the immunotherapy of ragweed hay fever. J.Allergy Clin. Immunol., 1982, 70 (4), 248-260.
201. Meriney, D. K.; Kothari, H.; Chinoy, P.; Grieco, M. H. The clinical and immunologic efficacy of immunotherapy with modified ragweed extract (allergoid) for ragweed hay fever. Ann. Allergy, 1986, 56 (1), 34-38.
202. Negro, J. M.; Wheeler, A. W.; Hernandez, J.; Youlten, L. J.; Pascual, A.; Garcia-Selles, F. J.; Pagan, J. A.; Lopez-Sanchez, J. D.; Miralles, J. C.; Sarrio, F.; Milan, J. M.; Contreras, L. G.; Vidal, D. Comparison of the efficacy and safety of two preseasonal regimens of glutaraldehyde modified, tyrosine-adsorbed parietaria pollen extract over a period of three years in monosensitive patients. Allergol. Immunopathol (Madr)., 1999, 27 (3), 153-164.
203. Tari, M. G.; Mancino, M.; Ghezzi, E.; Frank, E.; Cromwell, O. Immunotherapy with an alum-adsorbed Parietaria-pollen allergoid: a 2-year, double-blind, placebo-controlled study. Allergy, 1997, 52 (1), 65-74.
204. Bousquet, J.; Maasch, H.; Martinot, B.; Hejjaoui, A.; Wahl, R.; Michel, F. B. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. II. Comparison between parameters assessing the efficacy of immunotherapy. J. Allergy Clin. Immunol, 1988, 82 (3 Pt 1), 439-446.
205. Ariano, R.; Kroon, A. M.; Augeri, G.; Canonica, G. W.; Passalacqua, G. Long-term treatment with allergoid immunotherapy with Parietaria. Clinical and immunologic effects in a randomized, controlled trial. Allergy, 1999, 54 (4), 313-319.
206. Passalacqua, G.; Albano, M.; Fregonese, L.; Riccio, A.; Pronzato, C.; Mela, G. S.; Canonica, G. W. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in miteinduced rhinoconjunctivitis. Lancet, 1998, 351 (9103), 629-632.
207. Mistrello, G.; Brenna, O.; Roncarolo, D.; Zanoni, D.; Gentili, M.; Falagiani, P. Monomeric chemically modified allergens: immunologic and physicochemical characterization. Allergy, 1996, 51 (1), 8-15.
208. Mosges, R.; Ritter, B.; Kayoko, G.; Allekotte, S. Carbamylated monomeric allergoids as a therapeutic option for sublingual immunotherapy of dust mite-and grass pollen-induced allergic rhinoconjunctivitis: a systematic review of published trials with a metaanalysis of treatment using Lais(R) tablets. Acta. Dermatovenerol Alp.Panonica. Adriat., 2010, 19 (3), 3-10.
209. Gokmen, N. M.; Ersoy, R.; Gulbahar, O.; Ardeniz, O.; Sin, A.; Unsel, M.; Kokuludag, A. Desensitization Effect of Preseasonal Seven-Injection Allergoid Immunotherapy with Olive Pollen on Basophil Activation: The Efficacy of Olive Pollen-Specific Preseasonal Allergoid Immunotherapy on Basophils. Int. Arch. Allergy Immunol.,2012, 159 (1), 75-82.
210. Burastero, S. E.; Mistrello, G.; Falagiani, P.; Paolucci, C.; Breda, D.; Roncarolo, D.; Zanotta, S.; Monasterolo, G.; Rossi, R. E. Effect of sublingual immunotherapy with grass monomeric allergoid on allergen-specific T-cell proliferation and interleukin 10 production. Ann. Allergy Asthma Immunol., 2008, 100 (4), 343-350.
211. Cosmi, L.; Santarlasci, V.; Angeli, R.; Liotta, F.; Maggi, L.; Frosali, F.; Rossi, O.; Falagiani, P.; Riva, G.; Romagnani, S.; Annunziato, F.; Maggi, E. Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergenspecific immunoglobulin E and increases both interferon-gamma-and interleukin-10-production. Clin. Exp. Allergy, 2006, 36 (3), 261-272.
212. Klimek, L.; Dormann, D.; Jarman, E. R.; Cromwell, O.; Riechelmann, H.; Reske-Kunz, A. B. Short-term preseasonal birch pollen allergoid immunotherapy influences symptoms, specific nasal provocation and cytokine levels in nasal secretions, but not peripheral T-cell responses, in patients with allergic rhinitis. Clin. Exp. Allergy, 1999, 29 (10), 1326-1335.
213. Kahlert, H.; Grage-Griebenow, E.; Stuwe, H. T.; Cromwell, O.; Fiebig, H. T cell reactivity with allergoids: influence of the type of APC. J. Immunol., 2000, 165 (4), 1807-1815.
214. Starkl, P.; Felix, F.; Krishnamurthy, D.; Stremnitzer, C.; Roth-Walter, F.; Prickett, S. R.; Voskamp, A. L.; Willensdorfer, A.; Szalai, K.; Weichselbaumer, M.; O'Hehir, R. E.; Jensen-Jarolim, E. An unfolded variant of the major peanut allergen Ara h 2 with decreased anaphylactic potential. Clin. Exp. Allergy, 2012, 42 (12), 1801-1812.
215. Toda, M.; Reese, G.; Gadermaier, G.; Schulten, V.; Lauer, I.; Egger, M.; Briza, P.; Randow, S.; Wolfheimer, S.; Kigongo, V.; Del Mar San Miguel Moncin, M.; Fotisch, K.; Bohle, B.; Vieths, S.; Scheurer, S. Protein unfolding strongly modulates the allergenicity and immunogenicity of Pru p 3, the major peach allergen. J.Allergy Clin. Immunol., 2011, 128 (5), 1022-1030. e1021-1027.
216. Ferreira, F.; Hirtenlehner, K.; Jilek, A.; Godnik-Cvar, J.; Breiteneder, H.; Grimm, R.; Hoffmann-Sommergruber, K.; Scheiner, O.; Kraft, D.; Breitenbach, M.; Rheinberger, H. J.; Ebner, C. Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1: potential use of hypoallergenic isoforms for immunotherapy. J. Exp. Med., 1996, 183 (2), 599-609.
217. Wagner, S.; Radauer, C.; Bublin, M.; Hoffmann-Sommergruber, K.; Kopp, T.; Greisenegger, E. K.; Vogel, L.; Vieths, S.; Scheiner, O.; Breiteneder, H. Naturally occurring hypoallergenic Bet v 1 isoforms fail to induce IgE responses in individuals with birch pollen allergy. J. Allergy Clin. Immunol., 2008, 121 (1), 246-252.
218. Zakzuk, J.; Jimenez, S.; Cheong, N.; Puerta, L.; Lee, B. W.; Chua, K. Y.; Caraballo, L. Immunological characterization of a Blo t 12 isoallergen: identification of immunoglobulin E epitopes. Clin. Exp. Allergy, 2009, 39 (4), 608-616.
219. Ramos, M. L.; Huntley, J. J.; Maleki, S. J.; Ozias-Akins, P. Identification and characterization of a hypoallergenic ortholog of Ara h 2.01. Plant Mol. Biol., 2009, 69 (3), 325-335.
220. Zaborsky, N.; Brunner, M.; Wallner, M.; Himly, M.; Karl, T.; Schwarzenbacher, R.; Ferreira, F.; Achatz, G. Antigen aggregation decides the fate of the allergic immune response. J. Immunol., 2010, 184 (2), 725-735.
221. Yagami, T.; Osuna, H.; Kouno, M.; Haishima, Y.; Nakamura, A.; Ikezawa, Z. Significance of carbohydrate epitopes in a latex allergen with beta-1,3-glucanase activity. Int. Arch. Allergy Immunol., 2002, 129 (1), 27-37.
222. Olsson, S.; van Hage-Hamsten, M.; Whitley, P. Contribution of disulphide bonds to antigenicity of Lep d 2, the major allergen of the dust mite Lepidoglyphus destructor. Mol. Immunol., 1998, 35 (16), 1017-1023.
223. Smith, A. M.; Chapman, M. D.; Taketomi, E. A.; Platts-Mills, T. A.; Sung, S. S. Recombinant allergens for immunotherapy: A Der p 2 variant with reduced IgE reactivity retains T-cell epitopes. J. Allergy Clin. Immunol., 1998, 101 (3), 423-425.
224. Kauppinen, J.; Zeiler, T.; Rautiainen, J.; Rytkonen-Nissinen, M.; Taivainen, A.; Mantyjarvi, R.; Virtanen, T. Mutant derivatives of the main respiratory allergen of cow are less allergenic than the intact molecule. Clin.Exp.Allergy, 1999, 29 (7), 989-996.
225. Korematsu, S.; Tanaka, Y.; Hosoi, S.; Koyanagi, S.; Yokota, T.; Mikami, B.; Minato, N. C8/119S mutation of major mite allergen Derf-2 leads to degenerate secondary structure and molecular polymerization and induces potent and exclusive Th1 cell differentiation. J. Immunol, 2000, 165 (5), 2895-2902.
226. Bonura, A.; Amoroso, S.; Locorotondo, G.; Di Felice, G.; Tinghino, R.; Geraci, D.; Colombo, P. Hypoallergenic variants of the Parietaria judaica major allergen Par j 1: a member of the nonspecific lipid transfer protein plant family. Int. Arch. Allergy Immunol., 2001, 126 (1), 32-40.
227. Drew, A. C.; Eusebius, N. P.; Kenins, L.; de Silva, H. D.; Suphioglu, C.; Rolland, J. M.; O'Hehir R, E. Hypoallergenic variants of the major latex allergen Hev b 6.01 retaining human T lymphocyte reactivity. J. Immunol, 2004, 173 (9), 5872-5879.
228. Rolland, J. M.; O'Hehir, R. E. Latex allergy: a model for therapy. Clin. Exp. Allergy, 2008, 38 (6), 898-912.
229. Takai, T.; Yokota, T.; Yasue, M.; Nishiyama, C.; Yuuki, T.; Mori, A.; Okudaira, H.; Okumura, Y. Engineering of the major house dust mite allergen Der f 2 for allergen-specific immunotherapy. Nat. Biotechnol., 1997, 15 (8), 754-758.
230. Rolland, J. M.; Drew, A. C.; O'Hehir, R. E. Advances in development of hypoallergenic latex immunotherapy. Curr. Opin. Allergy Clin. Immunol., 2005, 5 (6), 544-551.
231. Kahlert, H.; Suck, R.; Weber, B.; Nandy, A.; Wald, M.; Keller, W.; Cromwell, O.; Fiebig, H. Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy. Int. Arch. Allergy Immunol., 2008, 145 (3), 193-206.
232. Ferreira, F.; Ebner, C.; Kramer, B.; Casari, G.; Briza, P.; Kungl, A. J.; Grimm, R.; Jahn-Schmid, B.; Breiteneder, H.; Kraft, D.; Breitenbach, M.; Rheinberger, H. J.; Scheiner, O. Modulation of IgE reactivity of allergens by site-directed mutagenesis: potential use of hypoallergenic variants for immunotherapy. FASEB J., 1998, 12 (2), 231-242.
233. Singh, M. B.; de Weerd, N.; Bhalla, P. L. Genetically engineered plant allergens with reduced anaphylactic activity. Int. Arch. Allergy Immunol., 1999, 119 (2), 75-85.
234. Rabjohn, P.; West, C. M.; Connaughton, C.; Sampson, H. A.; Helm, R. M.; Burks, A. W.; Bannon, G. A. Modification of peanut allergen Ara h 3: effects on IgE binding and T cell stimulation. Int. Arch. Allergy Immunol., 2002, 128 (1), 15-23.
235. Swoboda, I.; De Weerd, N.; Bhalla, P. L.; Niederberger, V.; Sperr, W. R.; Valent, P.; Kahlert, H.; Fiebig, H.; Verdino, P.; Keller, W.; Ebner, C.; Spitzauer, S.; Valenta, R.; Singh, M. B. Mutants of the major ryegrass pollen allergen, Lol p 5, with reduced IgE-binding capacity: candidates for grass pollen-specific immunotherapy. Eur. J. Immunol., 2002, 32 (1), 270-280.
236. Spangfort, M. D. Engineering and validation of recombinant proteins for allergen vaccines. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M, 2003, (94), 151-154. discussion 155.
237. Holm, J.; Gajhede, M.; Ferreras, M.; Henriksen, A.; Ipsen, H.; Larsen, J. N.; Lund, L.; Jacobi, H.; Millner, A.; Wurtzen, P. A.; Spangfort, M. D. Allergy vaccine engineering: epitope modulation of recombinant Bet v 1 reduces IgE binding but retains protein folding pattern for induction of protective blocking-antibody responses. J. Immunol., 2004, 173 (8), 5258-5267.
238. Schramm, G.; Kahlert, H.; Suck, R.; Weber, B.; Stuwe, H. T.; Muller, W. D.; Bufe, A.; Becker, W. M.; Schlaak, M. W.; Jager, L.; Cromwell, O.; Fiebig, H. Allergen engineering: variants of the timothy grass pollen allergen Phl p 5b with reduced IgEbinding capacity but conserved T cell reactivity. J. Immunol., 1999, 162 (4), 2406-2414.
239. Buhot, C.; Chenal, A.; Sanson, A.; Pouvelle-Moratille, S.; Gelb, M. H.; Menez, A.; Gillet, D.; Maillere, B. Alteration of the tertiary structure of the major bee venom allergen Api m 1 by multiple mutations is concomitant with low IgE reactivity. Protein. Sci., 2004, 13 (11), 2970-2978.
240. Kussebi, F.; Karamloo, F.; Rhyner, C.; Schmid-Grendelmeier, P.; Salagianni, M.; Mannhart, C.; Akdis, M.; Soldatova, L.; Markovic-Housley, Z.; Von Beust, B. R.; Kundig, T.; Kemeny, D. M.; Blaser, K.; Crameri, R.; Akdis, C. A. A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy. J. Allergy Clin. Immunol., 2005, 115 (2), 323-329.
241. King, T. P.; Jim, S. Y.; Monsalve, R. I.; Kagey-Sobotka, A.; Lichtenstein, L. M.; Spangfort, M. D. Recombinant allergens with reduced allergenicity but retaining immunogenicity of the natural allergens: hybrids of yellow jacket and paper wasp venom allergen antigen 5s. J. Immunol., 2001, 166 (10), 6057-6065.
242. Asturias, J. A.; Ibarrola, I.; Arilla, M. C.; Vidal, C.; Ferrer, A.; Gamboa, P. M.; Vinuela, J. E.; Sanz, M. L.; Andreu, C.; Martinez, A. Engineering of major house dust mite allergens Der p 1 and Der p 2 for allergen-specific immunotherapy. Clin. Exp. Allergy., 2009, 39 (7), 1088-1098.
243. Vrtala, S.; Hirtenlehner, K.; Susani, M.; Hufnagl, P.; Binder, B. R.; Vangelista, L.; Pastore, A.; Sperr, W. R.; Valent, P.; Ebner, C.; Kraft, D.; Valenta, R. Genetic engineering of recombinant hypoallergenic oligomers of the major birch pollen allergen, Bet v 1: candidates for specific immunotherapy. Int. Arch. Allergy Immunol., 1999, 118 (2-4), 218-219.
244. Zeiler, T.; Taivainen, A.; Rytkonen, M.; Rautiainen, J.; Karjalainen, H.; Mantyjarvi, R.; Tuomisto, L.; Virtanen, T. Recombinant allergen fragments as candidate preparations for allergen immunotherapy. J. Allergy Clin. Immunol., 1997, 100 (6 Pt 1), 721-727.
245. Vrtala, S.; Akdis, C. A.; Budak, F.; Akdis, M.; Blaser, K.; Kraft, D.; Valenta, R. T cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1, induce blocking antibodies. J. Immunol., 2000, 165 (11), 6653-6659.
246. Vrtala, S.; Fohr, M.; Campana, R.; Baumgartner, C.; Valent, P.; Valenta, R. Genetic engineering of trimers of hypoallergenic fragments of the major birch pollen allergen, Bet v 1, for allergy vaccination. Vaccine, 2011, 29 (11), 2140-2148.
247. Mothes-Luksch, N.; Stumvoll, S.; Linhart, B.; Focke, M.; Krauth, M. T.; Hauswirth, A.; Valent, P.; Verdino, P.; Pavkov, T.; Keller, W.; Grote, M.; Valenta, R. Disruption of allergenic activity of the major grass pollen allergen Phl p 2 by reassembly as a mosaic protein. J. Immunol., 2008, 181 (7), 4864-4873.
248. Chen, K. W.; Blatt, K.; Thomas, W. R.; Swoboda, I.; Valent, P.; Valenta, R.; Vrtala, S. Hypoallergenic Der p 1/Der p 2 combination vaccines for immunotherapy of house dust mite allergy. J. Allergy Clin. Immunol., 2012, 130 (2), 435-443. e434.
249. Okada, T.; Swoboda, I.; Bhalla, P. L.; Toriyama, K.; Singh, M. B. Engineering of hypoallergenic mutants of the Brassica pollen allergen, Bra r 1, for immunotherapy. FEBS Lett., 1998, 434 (3), 255-260.
250. Westritschnig, K.; Focke, M.; Verdino, P.; Goessler, W.; Keller, W.; Twardosz, A.; Mari, A.; Horak, F.; Wiedermann, U.; Hartl, A.; Thalhamer, J.; Sperr, W. R.; Valent, P.; Valenta, R. Generation of an allergy vaccine by disruption of the three-dimensional structure of the cross-reactive calcium-binding allergen, Phl p 7. J. Immunol., 2004, 172 (9), 5684-5692.
251. Swoboda, I.; Bugajska-Schretter, A.; Linhart, B.; Verdino, P.; Keller, W.; Schulmeister, U.; Sperr, W. R.; Valent, P.; Peltre, G.; Quirce, S.; Douladiris, N.; Papadopoulos, N. G.; Valenta, R.; Spitzauer, S. A recombinant hypoallergenic parvalbumin mutant for immunotherapy of IgE-mediated fish allergy. J. Immunol., 2007, 178 (10), 6290-6296.
252. Valenta, R.; Niederberger, V. Recombinant allergens for immunotherapy. J. Allergy Clin. Immunol., 2007, 119 (4), 826-830.
253. Valenta, R.; Linhart, B.; Swoboda, I.; Niederberger, V. Recombinant allergens for allergen-specific immunotherapy: 10 years anniversary of immunotherapy with recombinant allergens. Allergy, 2011, 66 (6), 775-783.
254. Zuidmeer-Jongejan, L.; Fernandez-Rivas, M.; Poulsen, L. K.; Neubauer, A.; Asturias, J.; Blom, L.; Boye, J.; Bindslev-Jensen, C.; Clausen, M.; Ferrara, R.; Garosi, P.; Huber, H.; Jensen, B. M.; Koppelman, S.; Kowalski, M. L.; Lewandowska-Polak, A.; Linhart, B.; Maillere, B.; Mari, A.; Martinez, A.; Mills, C. E.; Nicoletti, C.; Opstelten, D. J.; Papadopoulos, N. G.; Portoles, A.; Rigby, N.; Scala, E.; Schnoor, H. J.; Sigursdottir, S.; Stavroulakis, G.; Stolz, F.; Swoboda, I.; Valenta, R.; van den Hout, R.; Versteeg, S. A.; Witten, M.; van Ree, R. FAST: Towards safe and effective subcutaneous immunotherapy of persistent life-threatening food allergies. Clin. Transl. Allergy, 2012, 2 (1), 5.
255. Jahn-Schmid, B.; Siemann, U.; Zenker, A.; Bohle, B.; Messner, P.; Unger, F. M.; Sleytr, U. B.; Scheiner, O.; Kraft, D.; Ebner, C. Bet v 1, the major birch pollen allergen, conjugated to crystalline bacterial cell surface proteins, expands allergen-specific T cells of the Th1/Th0 phenotype in vitro by induction of IL-12. Int. Immunol., 1997, 9 (12), 1867-1874.
256. Gerstmayr, M.; Ilk, N.; Schabussova, I.; Jahn-Schmid, B.; Egelseer, E. M.; Sleytr, U. B.; Ebner, C.; Bohle, B. A novel approach to specific allergy treatment: the recombinant allergen-Slayer fusion protein rSbsC-Bet v 1 matures dendritic cells that prime Th0/Th1 and IL-10-producing regulatory T cells. J. Immunol., 2007, 179 (11), 7270-7275.
257. Hetzel, C.; Janssen, R.; Ely, S. J.; Kristensen, N. M.; Bunting, K.; Cooper, J. B.; Lamb, J. R.; Young, D. B.; Thole, J. E. An epitope delivery system for use with recombinant mycobacteria. Infect. Immun., 1998, 66 (8), 3643-3648.
258. Rask, C.; Holmgren, J.; Fredriksson, M.; Lindblad, M.; Nordstrom, I.; Sun, J. B.; Czerkinsky, C. Prolonged oral treatment with low doses of allergen conjugated to cholera toxin B subunit suppresses immunoglobulin E antibody responses in sensitized mice. Clin.Exp. Allergy, 2000, 30 (7), 1024-1032.
259. Lombardi, V.; Van Overtvelt, L.; Horiot, S.; Moussu, H.; Chabre, H.; Louise, A.; Balazuc, A. M.; Mascarell, L.; Moingeon, P. Tolllike receptor 2 agonist Pam3CSK4 enhances the induction of antigen-specific tolerance via the sublingual route. Clin. Exp. Allergy., 2008, 38 (11), 1819-1829.
260. Patel, P.; Salapatek, A. M. Pollinex Quattro: a novel and welltolerated, ultra short-course allergy vaccine. Expert. Rev. Vaccines, 2006, 5 (5), 617-629.
261. Puggioni, F.; Durham, S. R.; Francis, J. N. Monophosphoryl lipid A (MPL) promotes allergen-induced immune deviation in favour of Th1 responses. Allergy, 2005, 60 (5), 678-684.
262. Ismaili, J.; Rennesson, J.; Aksoy, E.; Vekemans, J.; Vincart, B.; Amraoui, Z.; Van Laethem, F.; Goldman, M.; Dubois, P. M. Monophosphoryl lipid A activates both human dendritic cells and T cells. J. Immunol., 2002, 168 (2), 926-932.
263. Wheeler, A. W.; Marshall, J. S.; Ulrich, J. T. A Th1-inducing adjuvant, MPL, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines. Int. Arch. Allergy Immunol., 2001, 126 (2), 135-139.
264. Drachenberg, K. J.; Wheeler, A. W.; Stuebner, P.; Horak, F. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy, 2001, 56 (6), 498-505.
265. Mills, K. H. Regulatory T cells: friend or foe in immunity to infection? Nat. Rev. Immunol., 2004, 4 (11), 841-855.
266. Mittag, D.; Varese, N.; Scholzen, A.; Mansell, A.; Barker, G.; Rice, G.; Rolland, J. M.; O'Hehir, R. E. TLR ligands of ryegrass pollen microbial contaminants enhance Th1 and Th2 responses and decrease induction of Foxp3(hi) regulatory T cells. Eur. J. Immunol., 2012.
267. Svirshchevskaya, E. V.; Alekseeva, L.; Marchenko, A.; Viskova, N.; Andronova, T. M.; Benevolenskii, S. V.; Kurup, V. P. Immune response modulation by recombinant peptides expressed in viruslike particles. Clin. Exp. Immunol., 2002, 127 (2), 199-205.
268. Hirschberg, S.; Layton, G. T.; Harris, S. J.; Savage, N.; Dallman, M. J.; Lamb, J. R. CD4(+) T cells induced by virus-like particles expressing a major T cell epitope down-regulate IL-5 production in an ongoing immune response to Der p 1 independently of IFNgamma production. Int. Immunol., 1999, 11 (12), 1927-1934.
269. Senti, G.; Johansen, P.; Haug, S.; Bull, C.; Gottschaller, C.; Muller, P.; Pfister, T.; Maurer, P.; Bachmann, M. F.; Graf, N.; Kundig, T. M. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Clin. Exp. Allergy, 2009, 39 (4), 562-570.
270. Edlmayr, J.; Niespodziana, K.; Focke-Tejkl, M.; Linhart, B.; Valenta, R. Allergen-specific immunotherapy: towards combination vaccines for allergic and infectious diseases. Curr. Top Microbiol. Immunol., 2011, 352, 121-140.
271. Kim, T. S.; DeKruyff, R. H.; Rupper, R.; Maecker, H. T.; Levy, S.; Umetsu, D. T. An ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigenspecific IgE production. J. Immunol., 1997, 158 (9), 4137-4144.
272. Maecker, H. T.; Hansen, G.; Walter, D. M.; DeKruyff, R. H.; Levy, S.; Umetsu, D. T. Vaccination with allergen-IL-18 fusion DNA protects against, and reverses established, airway hyperreactivity in a murine asthma model. J. Immunol., 2001, 166 (2), 959-965.
273. Kumar, M.; Behera, A. K.; Hu, J.; Lockey, R. F.; Mohapatra, S. S. IFN-gamma and IL-12 plasmid DNAs as vaccine adjuvant in a murine model of grass allergy. J. Allergy Clin. Immunol., 2001, 108 (3), 402-408.
274. Arora, N.; Gangal, S. V. Efficacy of liposome entrapped allergen in down regulation of IgE response in mice. Clin. Exp.Allergy, 1992, 22 (1), 35-42.
275. Sehra, S.; Chugh, L.; Gangal, S. V. Polarized TH1 responses by liposome-entrapped allergen and its potential in immunotherapy of allergic disorders. Clin. Ex. Allergy., 1998, 28 (12), 1530-1537.
276. Sehra, S.; Chugh, L.; Gangal, S. V. Role of liposomes in selective proliferation of splenic lymphocytes. Mol. Cell Biochem., 1998, 183 (1-2), 133-139.
277. Nigam, S.; Ghosh, P. C.; Sarma, P. U. Altered immune response to liposomal allergens of Aspergillus fumigatus in mice. Int. J. Pharm., 2002, 236 (1-2), 97-109.
278. Basomba, A.; Tabar, A. I.; de Rojas, D. H.; Garcia, B. E.; Alamar, R.; Olaguibel, J. M.; del Prado, J. M.; Martin, S.; Rico, P. Allergen vaccination with a liposome-encapsulated extract of Dermatophagoides pteronyssinus: a randomized, double-blind, placebocontrolled trial in asthmatic patients. J.Allergy Clin. Immunol., 2002, 109 (6), 943-948.
279. Kawakita, A.; Shirasaki, H.; Yasutomi, M.; Tokuriki, S.; Mayumi, M.; Naiki, H.; Ohshima, Y. Immunotherapy with oligomannosecoated liposomes ameliorates allergic symptoms in a murine food allergy model. Allergy, 2012, 67 (3), 371-379.
280. Sheng, K. C.; Kalkanidis, M.; Pouniotis, D. S.; Esparon, S.; Tang, C. K.; Apostolopoulos, V.; Pietersz, G. A. Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicity in vitro and in vivo. Eur. J. Immunol., 2008, 38 (2), 424-436.
281. Zhou, X.; Liu, B.; Yu, X.; Zha, X.; Zhang, X.; Chen, Y.; Wang, X.; Jin, Y.; Wu, Y.; Shan, Y.; Liu, J.; Kong, W.; Shen, J. Controlled release of PEI/DNA complexes from mannose-bearing chitosan microspheres as a potent delivery system to enhance immune response to HBV DNA vaccine. J. Control Release, 2007, 121 (3), 200-207.
282. Krieg, A. M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev.Immunol., 2002, 20, 709-760.
283. Spiegelberg, H. L.; Raz, E. DNA-based approaches to the treatment of allergies. Curr Opin Mol Ther, 2002, 4 (1), 64-71.
284. Kline, J. N. Eat dirt: CpG DNA and immunomodulation of asthma. Proc. Am. Thorac. Soc., 2007, 4 (3), 283-288.
285. Broide, D.; Raz, E. DNA-Based immunization for asthma. Int. Arch. Allergy Immunol., 1999, 118 (2-4), 453-456.
286. Jahn-Schmid, B.; Wiedermann, U.; Bohle, B.; Repa, A.; Kraft, D.; Ebner, C. Oligodeoxynucleotides containing CpG motifs modulate the allergic TH2 response of BALB/c mice to Bet v 1, the major birch pollen allergen. J. Allergy Clin. Immunol., 1999, 104 (5), 1015-1023.
287. Kohama, Y.; Akizuki, O.; Hagihara, K.; Yamada, E.; Yamamoto, H. Immunostimulatory oligodeoxynucleotide induces TH1 immune response and inhibition of IgE antibody production to cedar pollen allergens in mice. J. Allergy Clin. Immunol., 1999, 104 (6), 1231-1238.
288. Sur, S.; Wild, J. S.; Choudhury, B. K.; Sur, N.; Alam, R.; Klinman, D. M. Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides. J. Immunol., 1999, 162 (10), 6284-6293.
289. Tighe, H.; Takabayashi, K.; Schwartz, D.; Van Nest, G.; Tuck, S.; Eiden, J. J.; Kagey-Sobotka, A.; Creticos, P. S.; Lichtenstein, L. M.; Spiegelberg, H. L.; Raz, E. Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J. Allergy Clin. Immunol., 2000, 106 (1 Pt 1), 124-134.
290. Peng, Z.; Wang, H.; Mao, X.; HayGlass, K. T.; Simons, F. E. CpG oligodeoxynucleotide vaccination suppresses IgE induction but may fail to down-regulate ongoing IgE responses in mice. Int. Immunol., 2001, 13 (1), 3-11.
291. Broide, D.; Schwarze, J.; Tighe, H.; Gifford, T.; Nguyen, M. D.; Malek, S.; Van Uden, J.; Martin-Orozco, E.; Gelfand, E. W.; Raz, E. Immunostimulatory DNA sequences inhibit IL-5, eosinoph ilic inflammation, and airway hyperresponsiveness in mice. J. Immunol., 1998, 161 (12), 7054-7062.
292. Bohle, B.; Jahn-Schmid, B.; Maurer, D.; Kraft, D.; Ebner, C. Oligodeoxynucleotides containing CpG motifs induce IL-12, IL-18 and IFN-gamma production in cells from allergic individuals and inhibit IgE synthesis in vitro. Eur. J. Immunol., 1999, 29 (7), 2344-2353.
293. Pichyangkul, S.; Yongvanitchit, K.; Kum-arb, U.; Krieg, A. M.; Heppner, D. G.; Walsh, D. S. Whole blood cultures to assess the immunostimulatory activities of CpG oligodeoxynucleotides. J. Immunol Methods, 2001, 247 (1-2), 83-94.
294. Horner, A. A.; Nguyen, M. D.; Ronaghy, A.; Cinman, N.; Verbeek, S.; Raz, E. DNA-based vaccination reduces the risk of lethal anaphylactic hypersensitivity in mice. J. Allergy Clin. Immunol., 2000, 106 (2), 349-356.
295. Magone, M. T.; Chan, C. C.; Beck, L.; Whitcup, S. M.; Raz, E. Systemic or mucosal administration of immunostimulatory DNA inhibits early and late phases of murine allergic conjunctivitis. Eur. J. Immunol., 2000, 30 (7), 1841-1850.
296. Creticos, P. S.; Schroeder, J. T.; Hamilton, R. G.; Balcer-Whaley, S. L.; Khattignavong, A. P.; Lindblad, R.; Li, H.; Coffman, R.; Seyfert, V.; Eiden, J. J.; Broide, D. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N. Engl. J. Med., 2006, 355 (14), 1445-1455.
297. Raz, E.; Tighe, H.; Sato, Y.; Corr, M.; Dudler, J. A.; Roman, M.; Swain, S. L.; Spiegelberg, H. L.; Carson, D. A. Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc. Natl Acad.Sci.U S A., 1996, 93 (10), 5141-5145.
298. Hsu, C. H.; Chua, K. Y.; Tao, M. H.; Lai, Y. L.; Wu, H. D.; Huang, S. K.; Hsieh, K. H. Immunoprophylaxis of allergeninduced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunization. Nat. Med., 1996, 2 (5), 540-544.
299. Slater, J. E.; Paupore, E.; Zhang, Y. T.; Colberg-Poley, A. M. The latex allergen Hev b 5 transcript is widely distributed after subcutaneous injection in BALB/c mice of its DNA vaccine. J Allergy Clin. Immunol., 1998, 102 (3), 469-475.
300. Li, X.; Huang, C. K.; Schofield, B. H.; Burks, A. W.; Bannon, G. A.; Kim, K. H.; Huang, S. K.; Sampson, H. A. Strain-dependent induction of allergic sensitization caused by peanut allergen DNA immunization in mice. J. Immunol., 1999, 162 (5), 3045-3052.
301. Hartl, A.; Kiesslich, J.; Weiss, R.; Bernhaupt, A.; Mostbock, S.; Scheiblhofer, S.; Ebner, C.; Ferreira, F.; Thalhamer, J. Immune responses after immunization with plasmid DNA encoding Bet v 1, the major allergen of birch pollen. J. Allergy Clin. Immunol., 1999, 103 (1 Pt 1), 107-113.
302. Toda, M.; Sato, H.; Takebe, Y.; Taniguchi, Y.; Saito, S.; Inouye, S.; Takemori, T.; Sakaguchi, M. Inhibition of immunoglobulin E response to Japanese cedar pollen allergen (Cry j 1) in mice by DNA immunization: different outcomes dependent on the plasmid DNA inoculation method. Immunology, 2000, 99 (2), 179-186.
303. Kwon, S. S.; Kim, N.; Yoo, T. J. The effect of vaccination with DNA encoding murine T-cell epitopes on the Der p 1 and 2 induced immunoglobulin E synthesis. Allergy, 2001, 56 (8), 741-748.
304. Adel-Patient, K.; Creminon, C.; Boquet, D.; Wal, J. M.; Chatel, J. M. Genetic immunisation with bovine beta-lactoglobulin cDNA induces a preventive and persistent inhibition of specific anti-BLG IgE response in mice. Int. Arch. Allergy Immunol., 2001, 126 (1), 59-67.
305. Jilek, S.; Barbey, C.; Spertini, F.; Corthesy, B. Antigenindependent suppression of the allergic immune response to bee venom phospholipase A(2) by DNA vaccination in CBA/J mice. J. Immunol., 2001, 166 (5), 3612-3621.
306. Draghi, M.; Jarman, E. R.; Grifantini, R.; Galli-Stampino, L.; Lamb, J. R.; Valiante, N. M.; Grandi, G. Different profile of CD8+ effector T cells induced in Der p 1-allergic and naive mice by DNA vaccination. Eur. J. Immunol., 2002, 32 (12), 3720-3728.
307. Peng, H. J.; Su, S. N.; Chang, Z. N.; Chao, P. L.; Kuo, S. W.; Tsai, L. C. Induction of specific Th1 responses and suppression of IgE antibody formation by vaccination with plasmid DNA encoding Der f 11. Vaccine, 2002, 20 (13-14), 1761-1768.
308. Toda, M.; Kasai, M.; Hosokawa, H.; Nakano, N.; Taniguchi, Y.; Inouye, S.; Kaminogawa, S.; Takemori, T.; Sakaguchi, M. DNA vaccine using invariant chain gene for delivery of CD4+ T cell epitope peptide derived from Japanese cedar pollen allergen inhibits allergen-specific IgE response. Eur. J. Immunol., 2002, 32 (6), 1631-1639.
309. Roy, K.; Mao, H. Q.; Huang, S. K.; Leong, K. W. Oral gene delivery with chitosan--DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat. Med., 1999, 5 (4), 387-391.
310. Roesler, E.; Weiss, R.; Weinberger, E. E.; Fruehwirth, A.; Stoecklinger, A.; Mostbock, S.; Ferreira, F.; Thalhamer, J.; Scheiblhofer, S. Immunize and disappear-safety-optimized mRNA vaccination with a panel of 29 allergens. J. Allergy Clin.Immunol., 2009, 124 (5), 1070-1077. e1071-1011.
311. Gardner, L. M.; O'Hehir, R. E.; Rolland, J. M. T cell targeted allergen derivatives for improved efficacy and safety of specific immunotherapy for allergic disease. Curr. Med. Chem-Anti-Inflammatory & Anti-Allergy Agents, 2003, 2 351-365.